Destiny Pharma plc (GB:DEST) has released an update.
Destiny Pharma plc, a clinical-stage biotechnology company, will hold its 2024 Annual General Meeting (AGM) to discuss the progress and future of its XF-73 Nasal program, aimed at preventing post-surgical infections including MRSA. The company is exploring strategic options to advance the program through Phase 3 trials after receiving feedback from potential partners. Shareholders are invited to attend the AGM remotely and the event will include a presentation and Q&A session with the CEO.
For further insights into GB:DEST stock, check out TipRanks’ Stock Analysis page.
